Series A · Biotech · Cambridge, United Kingdom · Founded 2020 · 40–50 employees
Maxion Therapeutics is a Cambridge-based biotech company developing revolutionary KnotBody® technology that combines naturally occurring mini-proteins called knottins with antibodies to target ion channels and GPCRs. The company was co-founded by Dr. John McCafferty, co-inventor of antibody phage display technology that earned the 2018 Nobel Prize in Chemistry. Maxion recently raised $72 million in a Series A round led by General Catalyst, one of the largest European private biotech financings since early 2024. Their lead program MAX001 is in preclinical development for inflammatory diseases like atopic dermatitis and inflammatory bowel disease.
No open roles listed right now.